As with many western countries, New Zealand’s  drug laws are out of date and are causing more  harm than was originally intended. The laws carry  the shadow of a prohibitionist past, have failed to  keep up with innovations in drug production and  supply and do not relate well to modern  understandings of harm reduction and health  protection.

The challenge of Benzylpiperazine (BZP) ‘party pills’ in the late 1990s and early 2000s made deficiencies  in New Zealand’s drug law abundantly clear. No  framework for controlling BZP and other party pills could be found within existing laws and  regulations. An endless cat and mouse game began  between the Government and the ‘legal high’  industry, with new psychoactive substances (NPS)  coming onto the market as quickly as existing substances could be banned.

This prompted the New Zealand Government to order a review by the New Zealand Law Commission of the Misuse of Drugs Act 1975  (MODA).

The recommendations from this review led to New Zealand’s ground-breaking and worldleading Psychoactive Substances Act 2013.

New Zealand’s small population and remote location make for a poor and risky market for  international drug rings. Drugs like heroin and cocaine, which are present in other parts of the  world, are relatively rare. The creation of NPS continues a long history of New Zealanders making the most of available resources to create
substitutes for drugs that are unavailable.

It is fitting then, that New Zealand has become the first country to pass legislation that seeks to regulate NPS to ensure they are low risk, rather than to control them through prohibition and punitive measures.

The Psychoactive Substances Act 2013 has been generally well-received by politicians, the ‘legal high’ industry and the public. It is also receiving considerable attention from like-minded jurisdictions around the world.

As we shall see, if is far from a perfect or final solution, but it bodes extremely well for future drug policy development and reform, both here and overseas.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.